Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724659 | SCV000227546 | pathogenic | not provided | 2015-03-17 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000622333 | SCV000742795 | pathogenic | Inborn genetic diseases | 2017-07-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000724659 | SCV003300148 | pathogenic | not provided | 2024-01-30 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Leu93Valfs*89) in the CANT1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CANT1 are known to be pathogenic (PMID: 19853239, 21037275, 22539336). This variant is present in population databases (rs587776897, gnomAD 0.03%). This premature translational stop signal has been observed in individual(s) with Desbuquois dysplasia (PMID: 21654728). ClinVar contains an entry for this variant (Variation ID: 31015). For these reasons, this variant has been classified as Pathogenic. |
Gene |
RCV000724659 | SCV005325088 | pathogenic | not provided | 2023-12-24 | criteria provided, single submitter | clinical testing | Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 21654728, 31510824, 37107695, 34602954) |
OMIM | RCV000024007 | SCV000045298 | pathogenic | Desbuquois dysplasia 1 | 2011-11-01 | no assertion criteria provided | literature only |